Argus downgraded Zoetis from Buy to Hold
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/27/2026 | Buy → Hold | Argus | |
| 4/15/2026 | $145.00 | Buy | Citigroup |
| 1/22/2026 | $135.00 | Overweight → Neutral | Piper Sandler |
| 12/15/2025 | $135.00 | Buy → Neutral | BofA Securities |
| 12/9/2025 | $136.00 | Equal Weight | Barclays |
| 11/21/2025 | Sector Weight | KeyBanc Capital Markets | |
| 7/17/2025 | $155.00 | Outperform → Market Perform | Leerink Partners |
| 6/18/2025 | $160.00 | Buy → Hold | Stifel |
Argus downgraded Zoetis from Buy to Hold
Citigroup initiated coverage of Zoetis with a rating of Buy and set a new price target of $145.00
Piper Sandler downgraded Zoetis from Overweight to Neutral and set a new price target of $135.00
Up to 40% of dogs may have radiographic osteoarthritis - New long-acting monoclonal antibody therapy offers three months of osteoarthritis pain relief for dogs with a single injection Zoetis Inc. (NYSE:ZTS) today announced that it has recently launched Lenivia® (izenivetmab injection) in Canada and the European Union (EU) member states – a new long-acting monoclonal antibody (mAb) therapy designed to deliver up to three months of osteoarthritis (OA) pain management with a single subcutaneous injection. Backed by a decade of science and research, Lenivia demonstrated a sustained reduction in pain in a pivotal nine-month European field study, with effects observed from as early as Day 7 aft
Acquisition would strengthen Zoetis’ Global Diagnostics portfolio through teleradiology, imaging services, and workflow technology, advancing a more comprehensive end-to-end Virtual Reference Lab Zoetis Inc. today announced its agreement to acquire VitalRADS, a veterinary teleradiology services platform. Building on the partnership with VitalRADS that Zoetis announced in August 2025, this acquisition adds around-the-clock access to board-certified veterinary specialists through a cloud-based teleradiology platform. Integrating VitalRADS’ capabilities into Zoetis’ Global Diagnostics portfolio enhances Zoetis’ reference laboratory services, delivering AI-assisted report generation and quali
Recombinant vector vaccine protects chickens against Newcastle disease and Marek's disease in a single dose Zoetis Inc. (NYSE:ZTS) today announced that the European Commission (EC) has granted marketing authorization for Poulvac® Procerta® HVT-ND, a recombinant vector vaccine for the protection of chickens against Newcastle disease (ND) and Marek’s disease viruses. The vaccine can be administered either in ovo or by subcutaneous injection at hatch, providing protection against both diseases with a single dose. Newcastle disease is a notifiable disease under EU animal health regulations and a significant cause of mortality and production losses in commercial poultry, as evidenced by rece
For Immediate Release: January 13, 2022 Today, the U.S. Food and Drug Administration approved Solensia (frunevetmab injection), the first treatment for the control of pain associated with osteoarthritis in cats and the first monoclonal antibody (mAb) new animal drug approved by the FDA for use in any animal species. Frunevetmab, the active ingredient in Solensia, is a cat-specific monoclonal antibody (a type o
4 - Zoetis Inc. (0001555280) (Issuer)
4 - Zoetis Inc. (0001555280) (Issuer)
4 - Zoetis Inc. (0001555280) (Issuer)
4 - Zoetis Inc. (0001555280) (Issuer)
4 - Zoetis Inc. (0001555280) (Issuer)
4 - Zoetis Inc. (0001555280) (Issuer)
11-K - Zoetis Inc. (0001555280) (Filer)
SD - Zoetis Inc. (0001555280) (Filer)
8-K - Zoetis Inc. (0001555280) (Filer)
Dr. Rob Polzer to Retire at the End of the Year After 10-Year Distinguished Career of Advancing Veterinary Medicine and Innovation Zoetis Inc. (NYSE:ZTS) today announced that following a 10-year distinguished career dedicated to advancing veterinary medicine and innovation, Rob Polzer, Ph.D., Executive Vice President and President, Research and Development, has made the personal decision to retire at the end of 2025. After a planful succession process, Zoetis has appointed Kevin Esch, D.V.M, M.P.H., Ph.D., Dipl. ACVP (anatomic) to succeed Dr. Polzer in this role, effective January 1, 2026. Dr. Esch currently serves as Senior Vice President of Global Therapeutics at Zoetis and joined Zoe
Health entrepreneur brings her digital and artificial intelligence (AI) experience to Zoetis Board Zoetis Inc. (NYSE:ZTS) today announced the appointment of Stephanie Tilenius to its Board of Directors, effective as of December 1, 2025. Ms. Tilenius brings extensive experience in technology-forward, digital health organizations to the Zoetis Board. Ms. Tilenius is a serial entrepreneur and has founded several healthcare companies, including most recently a stealth company in the longevity AI space. Previously, she founded Vida Health, Inc., a leading B2B chronic care platform focusing on diabetes and obesity, and scaled it nationally for Fortune 500 companies, large payers and healthcar
Dean of the University of California, Davis School of Veterinary Medicine brings extensive and valuable experience in animal health to Zoetis Board Zoetis Inc. (NYSE:ZTS) today announced the election of Dr. Mark Stetter to its Board of Directors, effective as of the company's annual shareholder meeting on May 21, 2025. Dr. Stetter brings extensive experience in veterinary medicine and animal health, including as Dean of the University of California, Davis School of Veterinary Medicine, to the Zoetis Board. His career in animal health includes pets, livestock, exotic animals, research and wildlife. He will serve on the Board's Quality and Innovation Committee. "Dr. Stetter brings invaluab
SC 13G/A - Zoetis Inc. (0001555280) (Subject)
SC 13G/A - Zoetis Inc. (0001555280) (Subject)
SC 13G/A - Zoetis Inc. (0001555280) (Subject)
Zoetis Inc. (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Thursday, August 6, 2026. Chief Executive Officer Kristin Peck and Executive Vice President and Chief Financial Officer Wetteny Joseph will review second quarter 2026 financial results and respond to questions from financial analysts. Investors and the public may access the live webcast and corresponding slides by visiting the Zoetis website at https://investor.zoetis.com/events-presentations. Pre-registration for the webcast is available beginning today. A replay will be made available on August 6, 2026. About Zoetis Zoetis is the world’s leading animal health company, driven by a singular purpose: to
The Board of Directors of Zoetis Inc. (NYSE:ZTS) has declared a dividend of $0.53 per share for the third quarter of 2026. The dividend will be paid on Tuesday, September 1, 2026, to all holders of record of the Company's common stock as of the close of business on Monday, July 20, 2026. About Zoetis Zoetis is the world's leading animal health company, driven by a singular purpose: to nurture our world and humankind by advancing care for animals. With a legacy of nearly 75 years, Zoetis continues to pioneer ways to predict, prevent, detect, and treat animal illness, supporting veterinarians, livestock producers, and pet owners in over 100 countries. We integrate deep scientific expertis
Revenue of $2.3 Billion, Growing 3%, and Net Income of $601 Million, or $1.42 per Diluted Share, Flat and Increasing 6%, Respectively, on a Reported Basis Adjusted Net Income of $646 Million, or Adjusted Diluted EPS of $1.53 Flat Organic Operational Growth in Revenue and 1% Organic Operational Growth in Adjusted Net Income Revises Full Year 2026 Revenue Guidance to $9.680 - $9.960 Billion with Organic Operational Revenue Growth of 2% to 5% Revises Full Year 2026 Guidance for Organic Operational Growth in Adjusted Net Income to 2% to 6% Revises Guidance for Diluted EPS on an Adjusted Basis to $6.85 to $7.00 Zoetis Inc. (NYSE:ZTS), the world's leading animal health company,